Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant (HCT)

Next Previous
X
Search
Trial Profile

Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant (HCT)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Posoleucel (Primary)
  • Indications Adenovirus infections; Cytomegalovirus infections; Epstein-Barr virus infections; Haemorrhagic cystitis; Human herpesvirus 6 infections; Polyomavirus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors AlloVir

    • Most Recent Events

    • 16 May 2024 Last checked against ClinicalTrials.gov record.
    • 04 Feb 2024 This study has been discontinued in Italy (2023-12-22), according to European Clinical Trials Database record.
    • 02 Feb 2024 This study has been completed in France, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top